Commentary on the Abuse of Metal Chelation Therapy in Patients with Autism Spectrum Disorders
- 364 Downloads
Approximately half a million patients with autism spectrum disorders are subjected to chelation therapy in the US annually. The overwhelming majority of such cases are chelated for non-accepted medical indications. These patients may seek evaluation when a urine sample is assayed after the administration of a chelating agent and the values obtained have been improperly compared to references ranges for non-chelated urines, causing falsely elevated results. Legitimate practitioners confronted with such data must decide, preferably in consultation with the patient or their guardian(s), whether to do further testing using legitimate methodology or to simply dismiss the results of the improper testing. Bayesian principles tell us that further testing is likely to yield results within normal reference ranges. However, under some circumstances, it is useful to do such testing in order to demonstrate that there is no need for chelation therapy. Unnecessary chelation therapy is expensive, can cause significant acute adverse effects, and may be associated with long-term consequences.
KeywordsAutism spectrum disorder Chelation therapy Mercury Metal toxicity Elevated body burden of metal
This publication was supported by the cooperative agreement award number 1U61TS000117-04 from the Agency for Toxic Substances and Disease Registry (ATSDR). Its contents are the responsibility of the authors and do not necessarily represent the official views of the Agency for Toxic Substances and Disease Registry (ATSDR).
For the work under consideration for publication, Dr. Brent received an honorarium and reimbursement for travel through the ACMT/ATSDR Cooperative Agreement. Relevant financial activities outside the submitted work: Dr. Brent has been a consultant to the US National Vaccine program and was a witness, on behalf of the US Government, in the National Omnibus Vaccine Hearings.
- 1.Schultz ST (2010) Does thimerosal or other mercury exposure increase the risk for autism? Acta Neurobiol Exp 70:187–195Google Scholar
- 2.Institute of Medicine. Immunization Safety Review Vaccines and Autism. National Academies Press. Washington, D.C. 2004. http://images.nap.edu/openbook/030909237X/gifmid/RI.gif Accessed 15 July 2013
- 9.Shannon M, Grace A, Graef J (1989) Use of urinary lead concentration in interpretation of the EDTA mobilization test. Vet Human Toxicol 31:140–142Google Scholar
- 10.Charlton N, Wallace KL. American College of Medical Toxicology Position Statement on post-chelator challenge urinary metal testing. 2009. http://www.acmt.net/cgi/page.cgi/zine_service.html?aid=2999&zine=show Accessed 17 July 2013
- 11.Goldman RH, Woolf A. Chelation therapy–guidance for the general public. 2012. http://www.clintox.org/documents/publicinformation/PEHSU_AACTchelationPublicFactsheet2012.pdf Accessed 17 July 2013
- 16.Doja A, Roberts W (2006) Immunizations and autism: a review of the literature. Can J Neuro Sci 33:341–346Google Scholar
- 17.Moel DL, Kumar K (1982) Reversible nephrotoxic reactions to a combined 2,3 dimercapto-1-propanol and calcium disodium ethylenediaminetetraacetic acid regimen in asymptomatic children with elevated blood lead levels. PEDS 70:259–262Google Scholar
- 18.Stangle DE, Smith DR, Beaudin SA, Strawderman MS, Levitsky DA, Strupp BJ (2007) Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats, but produces lasting cognitive impairment in the absence of lead exposure. Enviro Health Persp 118:201–209Google Scholar